Comparative Pharmacology
Head-to-head clinical analysis: ADPHEN versus PLEGINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADPHEN versus PLEGINE.
ADPHEN vs PLEGINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adphen is a combination of phentermine hydrochloride and diethylpropion hydrochloride. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, thereby reducing food intake. Diethylpropion also has sympathomimetic activity, though its exact mechanism is not fully understood.
Plegine (phendimetrazine) is a sympathomimetic amine that acts as an anorectic agent. It stimulates the hypothalamus to release norepinephrine and dopamine, thereby suppressing appetite. The exact mechanism is thought to involve the release of catecholamines from presynaptic nerve terminals in the lateral hypothalamic feeding center, leading to decreased food intake.
5 mg orally once daily, titrated to a maximum of 10 mg once daily as tolerated.
25-50 mg orally once daily at bedtime, maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 4–8 hours (mean 6 hours). Clinical context: Steady-state achieved after 24–48 hours of repeated dosing.
Primarily renal (70-90% as unchanged drug) with minor biliary (10-15% as metabolites). Fecal elimination is negligible (<5%).
Renal: 40% unchanged; Hepatic metabolism: 60% (biliary/fecal elimination of metabolites).
Category C
Category C
Anorexiant
Anorexiant